Literature DB >> 32728909

Factors influencing cognitive performance after 1-year treatment with direct oral anticoagulant in patients with atrial fibrillation and previous ischemic stroke: a pilot study.

Manuel Cappellari1, Stefano Forlivesi2, Chiara Zucchella3, Valeria Valbusa3, Giulia Sajeva3, Anna Maria Musso3, Nicola Micheletti3, Giampaolo Tomelleri3, Tommaso Bovi3, Bruno Bonetti3, Paolo Bovi3.   

Abstract

Anticoagulant treatment as stroke prevention, particularly direct oral anticoagulant (DOAC), may reduce the risk of dementia in patients with atrial fibrillation (AF). We aimed to assess factors influencing cognitive performance after 1-year treatment with DOAC in patients with AF and previous ischemic stroke. We recruited 33 ischemic stroke patients who were discharged from Verona Stroke Unit with diagnosis of AF and prescription of treatment with DOAC. For each cognitive test, we estimated the effect of T0 (first session) variables on T1 (1-year session) cognitive performance using ordinal logistic regression fitted to a 1 point-shift from 4 to 0 on ESs. The effect of T0 clinical variables was presented as odds ratio (OR) with 95% confidence interval (CI) after adjustment for T0 total score of the corresponding cognitive test. Sustained AF (OR: 4.259, 95% CI 1.071-16.942) and ischemic heart disease (OR: 6.654, 95% CI 1.329-33.300) showed a significant effect on T1 MoCA Test; congestive heart failure on T1 RAVLT Immediate recall (OR: 9.128, 95% CI 1.055-78.995), T1 RAVLT Delayed recall (OR: 7.134, 95% CI 1.214-52.760), and T1 Trail Making Test (Part A) (OR: 16.989, 95% CI 1.765-163.565); sustained AF (OR: 5.055, 95% CI 1.224-20.878) and hyperlipidemia (OR: 4.764, 95% CI 1.175-19.310) on T1 Digit span forward Test; ischemic heart disease (aOR: 8.460, 95% CI 1.364-52.471) on T1 Stroop Color and Word Test (time); Dabigatran use (aOR: 0.084, 95% CI 0.013-0.544) on FAB; age ≥ 75 years (aOR: 0.058, 95% CI 0.006-0.563) and hyperlipidemia (aOR: 5.809, 95% CI 1.059-31.870) on T1 Phonemic word fluency Test; female sex (aOR: 6.105, 95% CI 1.146-32.519), hyperlipidemia (aOR: 21.099, 95% CI 2.773-160.564), total Modified Fazekas Scale score > 1 (aOR: 78.530, 95% CI 3.131-1969.512) on Semantic word fluency Test. Sustained AF, ischemic heart disease, congestive heart failure, hyperlipidemia, and female sex were the factors influencing cognitive performance after 1-year treatment with DOAC in patients with AF and previous ischemic stroke. Modified Fazekas Scale score in the first session was the only radiological variable that had a significant effect on cognitive performance.

Entities:  

Keywords:  Atrial fibrillation; Cognitive impairment; Dementia; Direct oral anticoagulant; Stroke

Year:  2021        PMID: 32728909     DOI: 10.1007/s11239-020-02233-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  3 in total

1.  Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming.

Authors:  T N Tombaugh; J Kozak; L Rees
Journal:  Arch Clin Neuropsychol       Date:  1999-02       Impact factor: 2.813

Review 2.  Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.

Authors:  Eric E Smith; Gustavo Saposnik; Geert Jan Biessels; Fergus N Doubal; Myriam Fornage; Philip B Gorelick; Steven M Greenberg; Randall T Higashida; Scott E Kasner; Sudha Seshadri
Journal:  Stroke       Date:  2016-12-15       Impact factor: 10.170

3.  Association of Oral Anticoagulant Type With Risk of Dementia Among Patients With Nonvalvular Atrial Fibrillation.

Authors:  Nemin Chen; Pamela L Lutsey; Richard F MacLehose; J'Neka S Claxton; Faye L Norby; Alanna M Chamberlain; Lindsay G S Bengtson; Wesley T O'Neal; Lin Y Chen; Alvaro Alonso
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

  3 in total
  1 in total

1.  Butylphthalide soft capsules combined with modified tonic exercise therapy on neurological function and ability of daily living of patients with stroke hemiplegia.

Authors:  You Lv; Qingxiu Zhang; Liangqun Rong; Xiu'e Wei; Haiyan Liu; Zhining Li
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.